XTL Halts Clinical Trial
XTL Biopharmaceuticals Ltd. (XTLB) halted clinical trials of its Hepatitis C treatment due to disappointing results. The stock price plunged 63 cents to close at $2.90.
posted by FC Market News at 2:59 PM
0 Comments:
Post a Comment
<< Home